Press Releases

Agilex Biolabs, Australia's largest and most technologically advanced regulated bioanalytical laboratory for clinical trials today announced that the Premier of South Australia the Hon Steven Marshall MP has launched its new $1.5m vaccine and immuno-biology laboratory. The facility, the most sophisticated in APAC, will attract biotechs and pharma from around the world for advanced clinical research. Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts, and Texas. Established in 2009 in the Bay Area, LakePharma applies its range of technology platforms to advance projects from discovery to development to

Contract development and manufacturing organisation (CDMO) Idifarma has launched a new service to deliver an accelerated, effective path to clinic for innovative molecules. Simply to Clinic™ uses Idifarma's expertise in oral standard and highly potent drugs to take projects from pre-formulation development through to clinical trial implementation, offering tailored services to develop, scale and manufacture product all under one roof at the facility in Pamplona, Spain.

Aptamer Group, the developer of Optimer™ therapeutics and diagnostics, has secured a contract with a top five global pharmaceutical company to develop Optimers to support the development of a novel vaccine candidate for neurodegenerative disease. The agreement includes an initial upfront payment to Aptamer Group with long term recurring licensing fees for over 10 years upon implementation of the assay into the partner’s global vaccine manufacturing processes. A

Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for selinexor, a first-in-class XPO1 inhibitor, for three indications: in combination with bortezomib and dexamethasone (XVd), or in combination with dexamethaso

GT Molecular, an industry leader in wastewater testing and multiplex, ultrasensitive PCR assays for cancer and pathogen epidemiology, has started shipping its sensitive PCR tests to monitor the coronavirus Delta variant (B.1.617.2). The variant was first identified in India in December of 2020 and has been designated a variant of concern by the WHO due to extremely high transmissibility.  Since its initial detection in the US in March of 2021, the Delta variant has spread rapidly and is

EVIO Inc. is pleased to announce that is has entered into a Letter of Intent to acquire Leading Edge Pharms, Inc. (LEP) of Henderson, Nevada. LEP is a biotechnology company focused on the research, development, and commercialization of novel cannabinoid therapies and innovative drug delivery systems that provide safe and effective topical solutions for pain management. LEP offers proprietary formulations and a non-systemic delivery system to enhance the permeation and relief process

Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level (~20ng/mL). Binding analyses project that AR-712 will be effective against all variants on the U.S. Centers for Disease Control's Variants of Interest and Variants of Concern lists.&n

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase II clinical trial for androgenetic alopecia(AGA) to be conducted in the US. The phase II trial is a randomized, double-blind, vehicle-controlled, parallel group study,  designed to evaluate the efficacy and safety of pyrilutamide in male s

Patient-oriented innovations and cases of the processes digitalization are presented at the Healthcare Automation and Digitalization Congress 2021 (AUTOMA+ Healthcare Edition 2021). The Congress takes place on September, 27-28, 2021, and gathers hospitals, healthcare providers, and pharmaceutical companies to network and share solutions regarding the personalized medicine developments and digital healthcare transformation. Last two years a lot of